Why nephrology marketing is different
Dialysis as a recurring
revenue marketing target.
No outpatient service in Indian healthcare generates more recurring, predictable revenue than dialysis. A CKD Stage 5 patient on haemodialysis attends 3 sessions per week — 12 sessions per month, 144 sessions per year — at ₹1,200–₹3,500 per session. A single dialysis patient generates ₹1.7L–₹5L in annual service revenue, year after year.
The marketing implication: acquiring one dialysis patient is worth significantly more than acquiring a one-time surgical patient. A CPQL of ₹3,000–₹8,000 for a dialysis patient is commercially justified by 5+ years of recurring revenue. ICG's dialysis centre clients target CPQL at 2–5% of year-1 dialysis revenue — a conservative acquisition cost that compounds as the patient relationship extends.
Dialysis centre marketing focuses on: proximity (patients attend 3×/week — maximum 5–8km radius is typical), quality signals (water quality certification, HD machine brand, nephrologist supervision frequency), comfort signals (chair type, air conditioning, viewing screens — the experience matters for sessions that last 3–4 hours), and insurance/PM-JAY acceptance.
CKD content marketing: the 2–7 year education opportunity
Most CKD patients are diagnosed at Stage 1–3 — often detected incidentally during a diabetic or hypertensive check-up. At this stage, they need education (what is CKD, what does GFR mean, how does diet affect kidney function) but not specialist intervention. They will seek specialist care at Stage 3–5, which may be 2–7 years away.
Content marketing that educates CKD patients at Stage 1–3 builds brand authority over this long window. When Stage 3 patients begin searching for nephrologists, the centre whose content has been their kidney health resource is the default choice.
Kidney transplant: the compliance minefield
Kidney transplant marketing is the most compliance-sensitive area in nephrology. The intersection of THO Act 1994 (regulating organ transplantation and prohibiting commercial organ trading), NMC Ethics Code (outcome promises), and DPDP Act (most sensitive personal data category) creates a compliance framework that requires careful navigation.
ICG's kidney transplant content is limited to: what is kidney transplantation, who is a candidate, the transplant evaluation process, living donor vs deceased donor (factual description only, no donor recruitment messaging), what to expect during transplant workup, post-transplant care requirements. No outcome claims, no donor recruitment, no comparative survival data presented as institutional marketing.
